Biotechnology News

The first patient dosing has been completed in a phase 3 study of PD-1/VEGF bsAb (JS207) in combination with CTLA-4 mAb (JS007) for the treatment of HCC.

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today...

WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...

24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned...

FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key...

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene...

Novastra Therapeutics to present first-in-human data for its first candidate in a novel category of cancer immune therapy at SITC Annual Meeting 2026.

WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic,...

美國麻塞諸塞州沃爾瑟姆, Oct. 29, 2026 (GLOBE NEWSWIRE) --...

美国马萨诸塞州沃尔瑟姆, Oct. 29, 2026 (GLOBE NEWSWIRE) --...